
Michael D Reily

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7745316/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	NMR-Based Assay for the <i>Ex Vivo</i> Determination of Soluble CD73 Activity in Serum. Analytical Chemistry, 2020, 92, 14501-14508.	3.2	1
2	Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. Obesity, 2017, 25, 1069-1076.	1.5	41
3	The utility of stable isotope labeled (SIL) analogues in the bioanalysis of endogenous compounds by LC-MS applied to the study of bile acids in a metabolomics assay. Analytical Biochemistry, 2016, 503, 71-78.	1.1	16
4	Metabolomics in the pharmaceutical industry. Drug Discovery Today: Technologies, 2015, 13, 25-31.	4.0	16
5	Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids, 2015, 47, 603-615.	1.2	175
6	1H NMR-based lipidomics of rodent fur: species-specific lipid profiles and SCD1 inhibitor-related dermal toxicity. Journal of Lipid Research, 2014, 55, 1366-1374.	2.0	4
7	Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2014, 59, 365-374.	1.1	39
8	NMR Methods for Metabolomics of Mammalian Cell Culture Bioreactors. Methods in Molecular Biology, 2014, 1104, 223-236.	0.4	8
9	Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicology and Applied Pharmacology, 2013, 268, 132-140.	1.3	153
10	The Current Status of Metabolomics in Drug Discovery and Development. Drug Development Research, 2012, 73, 535-546.	1.4	9
11	Intra- and Interlaboratory Reproducibility of Ultra Performance Liquid Chromatography–Time-of-Flight Mass Spectrometry for Urinary Metabolic Profiling. Analytical Chemistry, 2012, 84, 2424-2432.	3.2	44
12	Metabolomic and Transcriptomic Changes Induced by Overnight (16 h) Fasting in Male and Female Spragueâ^'Dawley Rats. Chemical Research in Toxicology, 2011, 24, 481-487.	1.7	33
13	NMR-based metabolomics of mammalian cell and tissue cultures. Journal of Biomolecular NMR, 2011, 49, 195-206.	1.6	63
14	Advances in mass spectrometry applied to pharmaceutical metabolomics. Analytical and Bioanalytical Chemistry, 2011, 399, 2645-2653.	1.9	61
15	Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling. Analytical Biochemistry, 2011, 410, 84-91.	1.1	46
16	Metabolomics in Toxicology: Preclinical and Clinical Applications. Toxicological Sciences, 2011, 120, S146-S170.	1.4	177
17	NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST. Bioanalysis, 2010, 2, 1263-1276.	0.6	25
18	Ultra Performance Liquid Chromatography-Mass Spectrometry Profiling of Bile Acid Metabolites in Biofluids: Application to Experimental Toxicology Studies. Analytical Chemistry, 2010, 82, 5282-5289.	3.2	89

MICHAEL D REILY

#	Article	IF	CITATIONS
19	Chemical shift calibration of ¹ H MAS NMR liver tissue spectra exemplified using a study of glycine protection of galactosamine toxicity. Magnetic Resonance in Chemistry, 2009, 47, S47-53.	1.1	13
20	Normalization strategies for metabonomic analysis of urine samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 547-552.	1.2	277
21	Mechanistic Aspects and Novel Biomarkers of Responder and Non-Responder Phenotypes in Galactosamine-Induced Hepatitis. Journal of Proteome Research, 2009, 8, 5175-5187.	1.8	39
22	Quantitative evaluation of sebum lipid components with nuclear magnetic resonance. Journal of Lipid Research, 2008, 49, 686-692.	2.0	57
23	Metabonomics in Pharmaceutical Discovery and Development. Journal of Proteome Research, 2007, 6, 526-539.	1.8	98
24	Heteronuclear ¹ Hâ^' ³¹ P Statistical Total Correlation NMR Spectroscopy of Intact Liver for Metabolic Biomarker Assignment:  Application to Galactosamine-Induced Hepatotoxicity. Analytical Chemistry, 2007, 79, 8956-8966.	3.2	58
25	Metabonomics in Preclinical Pharmaceutical Discovery and Development. , 2007, , 241-277.		2
26	Metabonomic Evaluation of Schaedler Altered Microflora Rats. Chemical Research in Toxicology, 2007, 20, 1388-1392.	1.7	25
27	Determination of Degradation Pathways and Kinetics of Acyl Glucuronides by NMR Spectroscopy. Chemical Research in Toxicology, 2007, 20, 876-886.	1.7	63
28	Metabonomic Evaluation of Metabolic Dysregulation in Rats Induced by PF 376304, a Novel Inhibitor of Phosphoinositide 3-Kinase. Chemical Research in Toxicology, 2007, 20, 1871-1877.	1.7	6
29	Improving NMR sensitivity by use of salt-tolerant cryogenically cooled probes. Analytical and Bioanalytical Chemistry, 2007, 387, 529-532.	1.9	29
30	Evaluation of NMR spectral data of urine in conjunction with measured clinical chemistry and histopathology parameters to assess the effects of liver and kidney toxicants. Metabolomics, 2007, 3, 87-100.	1.4	18
31	Proposed minimum reporting standards for chemical analysis. Metabolomics, 2007, 3, 211-221.	1.4	3,589
32	DFTMP, an NMR Reagent for Assessing the Near-Neutral pH of Biological Samples. Journal of the American Chemical Society, 2006, 128, 12360-12361.	6.6	41
33	Communication Regarding Metabonomic Identification of Two Distinct Phenotypes in Sprague-Dawley (Crl:CD(SD)) Rats. Toxicological Sciences, 2006, 91, 309-309.	1.4	11
34	Mechanisms and Biomarkers of Cardiovascular Injury Induced by Phosphodiesterase Inhibitor III SK&F 95654 in the Spontaneously Hypertensive Rat. Toxicologic Pathology, 2006, 34, 152-163.	0.9	40
35	Summary recommendations for standardization and reporting of metabolic analyses. Nature Biotechnology, 2005, 23, 833-838.	9.4	261
36	Metabonomic Identification of Two Distinct Phenotypes in Sprague-Dawley (Crl:CD(SD)) Rats. Toxicological Sciences, 2005, 87, 277-284.	1.4	86

MICHAEL D REILY

#	Article	IF	CITATIONS
37	Metabonomics in preclinical drug development. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 363-376.	1.5	33
38	METABOLIC ACTIVATION OF TROGLITAZONE: IDENTIFICATION OF A REACTIVE METABOLITE AND MECHANISMS INVOLVED. Drug Metabolism and Disposition, 2004, 32, 639-646.	1.7	115
39	Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicology and Applied Pharmacology, 2003, 187, 137-146.	1.3	374
40	Effect of Dexamethasone on the Metabonomics Profile Associated with Phosphodiesterase Inhibitor-Induced Vascular Lesions in Rats. Toxicology and Applied Pharmacology, 2002, 183, 108-116.	1.3	53
41	In Vivo Toxicity Screening Programs Using Metabonomics. Combinatorial Chemistry and High Throughput Screening, 2002, 5, 651-662.	0.6	50
42	NMR of biofluids and pattern recognition: assessing the impact of NMR parameters on the principal component analysis of urine from rat and mouse. Journal of Pharmaceutical and Biomedical Analysis, 2001, 26, 463-476.	1.4	74
43	Metabonomic Assessment of Vasculitis in Rats. Cardiovascular Toxicology, 2001, 1, 07-20.	1.1	51
44	[5] Nuclear magnetic resonance spectroscopy of peptide ion channel ligands: Cloning and expression as aid to evaluation of structural and dynamic properties. Methods in Enzymology, 1999, 294, 92-117.	0.4	3
45	Design of a Potent Combined Pseudopeptide Endothelin-A/Endothelin-B Receptor Antagonist, Ac-dBhg16-Leu-Asp-Ile-[NMe]IIe-Trp21(PD 156252):Â Examination of Its Pharmacokinetic and Spectral Properties. Journal of Medicinal Chemistry, 1997, 40, 2228-2240.	2.9	97
46	Biophysical Characterization of Zinc Ejection from HIV Nucleocapsid Protein by Anti-HIV 2,2â€~-Dithiobis[benzamides] and Benzisothiazolones. Journal of Medicinal Chemistry, 1996, 39, 4313-4320.	2.9	97
47	Three-Dimensional Structure Analysis of μ-Agatoxins: Further Evidence for Common Motifs among Neurotoxins with Diverse Ion Channel Specificitiesâ€. Biochemistry, 1996, 35, 2836-2844.	1.2	83
48	Identification of a 3-Hydroxylated Tacrine Metabolite in Rat and Man:  Metabolic Profiling Implications and Pharmacology. Journal of Medicinal Chemistry, 1996, 39, 3014-3018.	2.9	12
49	The solution structure of ?-Aga-IVB, a P-type calcium channel antagonist from venom of the funnel web spider, Agelenopsis aperta. Journal of Biomolecular NMR, 1995, 5, 122-32.	1.6	43
50	Structure-activity and biophysical studies of the C-terminal hexapeptide of endothelin. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 967-972.	1.0	3
51	Structure-activity relationships for P-type calcium channel-selective ω-agatoxins. Nature Structural and Molecular Biology, 1994, 1, 853-856.	3.6	23
52	Photodecomposition of CI-981, an HMG-CoA reductase inhibitor. Tetrahedron, 1993, 49, 1979-1984.	1.0	10
53	Structure-induced carbon-13 chemical shifts: a sensitive measure of transient localized secondary structure in peptides. Journal of the American Chemical Society, 1992, 114, 6251-6252.	6.6	40
54	The solution structure of a cyclic endothelin antagonist, BQ-123, based on 1 H-1 H and 13 H-1 H three bond oupling constants. FEBS Letters, 1992, 300, 136-140.	1.3	40

MICHAEL D REILY

#	Article	IF	CITATIONS
55	Design, synthesis and solution structure of a renin inhibitor Structural constraints from NOE, and homonuclear and heteronuclear coupling constants combined with distance geometry calculations. FEBS Letters, 1992, 302, 97-103.	1.3	9
56	The conformation of endothelin-1 in aqueous solution: NMR-Derived constraints combined with distance geometry and molecular dynamics calculations. Biochemical and Biophysical Research Communications, 1991, 178, 570-577.	1.0	51
57	An improved synthesis of anticancer benzothiopyranoindazoles. An efficient large-scale β-aminoethylation procedure. Journal of Heterocyclic Chemistry, 1991, 28, 517-527.	1.4	10
58	Analysis of rat amylin amide from commercial sources: Identification of a mercury complex Bioorganic and Medicinal Chemistry Letters, 1991, 1, 415-420.	1.0	7
59	Pt-DNA Interactions: Oligonucleotide Models. , 1991, , 101-114.		4
60	1H,13C, and 15N resonance assignments for a ferrocytochrome c553 heme by multinuclear NMR spectroscopy. Archives of Biochemistry and Biophysics, 1990, 276, 369-373.	1.4	12
61	Anticancer anilinoacridines. A process synthesis of the disubstituted amsacrine analog Clâ€921. Journal of Heterocyclic Chemistry, 1989, 26, 1469-1476.	1.4	15
62	Concerted two-dimensional NMR approaches to hydrogen-1, carbon-13, and nitrogen-15 resonance assignments in proteins. Biochemistry, 1989, 28, 230-236.	1.2	61
63	31P NMR investigation of fourteen self-complementary oligodeoxyribonucleotides (8-mer to 14-mer) treated with platinum complexes: the downfield 31P NMR signal characteristic of anti-cancer drugs is observed only for molecules with adjacent G residues. Inorganica Chimica Acta, 1987, 137, 1-13.	1.2	10
64	Phosphorus-31 and proton NMR spectroscopic studies of platinum adducts of poly(I).poly(C). The antitumor agent cis-dichlorodiammineplatinum forms an N7,N7 bis-adduct. Journal of the American Chemical Society, 1985, 107, 4916-4924.	6.6	24
65	Evidence for similar structural changes on binding of platinum anti-tumor agents to DNA and nucleosomes. FEBS Letters, 1984, 176, 389-392.	1.3	22